Table 2 CD4 counts and HIV-1 viral load range while on anti-TNF therapy and duration of anti-TNF therapy
Patient12345678
Duration anti-TNF treatment (months)502.5481134125513
Years of anti-TNF treatment2003–200720042003–20072003–20042004–20072004–20052003–20072006–2007
Still followedYesYesYesNoYesNoYesYes
Lowest CD4 count on anti-TNF treatment (cells/mm3) range3576348009237501082240382
Highest HIV-1 viral load on anti-TNF treatment (copies/ml)103845820<400428,503<400<50<400
Most recent CD4 count (cells/mm3) (date)538 (8/07)690 (12/06)748 (7/07)1073 (1/04)741 (7/07)1082 (11/05)417 (4/07)456 (5/07)
Most recent HIV-1 viral load (copies/mm3) (date)<400 (8/07)<400 (12/06)<400 (7/07)<400 (1/04)54227 (7/07)<400 (11/05)<50 (4/07)<400 (9/07)
Anti-TNF agents used*EtanerceptEtanerceptEtanercept Adalimumab InfliximabEtanerceptEtanercept Adalimumab InfliximabEtanerceptEtanercept InfliximabEtanercept Adalimumab Infliximab
DMARDs used during anti-TNF treatmentMTX 15 mg/week, LEF 20 mg/dayNoneSSZ 3 g/dayMTX 15 mg/weekMTX 15 mg/week LEF 20 mg/dayMTX 15 mg/weekMTX 15 mg/weekSSZ 2 g/day, MTX 12.5 mg/week
Clinical response to anti-TNF treatment†ExcellentTransientPartialExcellentEtanercept—transient Infliximab—excellent Adalimumab—partialExcellentEtanercept—none Infliximab—excellentPartial (etanercept and adalimumab) infliximab—excellent
Complications of anti-TNF treatmentNoneNoneNoneAcute anterior uveitisTransient rise in viral RNA, infusion reaction (infliximab)NoneFacial abscess (infliximab)etanercept allergy
  • TNF, tumour necrosis factor; DMARDs, disease modifying antirheumatic drugs; LEF, leflunomide; SSZ, sulfasalazine; MTX, methotrexate.

  • *Anti-TNF agents are listed in the order they were used by the patient.

  • †After anti-TNF treatment only one patient remained on prednisone (no. 1), who was able to reduce his dose to 5 mg/day.